8-K

UNIVERSAL HEALTH SERVICES INC (UHS)

8-K 2024-02-27 For: 2024-02-27
View Original
Added on April 04, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2024

UNIVERSAL HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

Delaware 1-10765 23-2077891
(State or other jurisdiction of (Commission (I.R.S. Employer
Incorporation or Organization) File Number) Identification No.)

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania 19406

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code (610) 768-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class B Common Stock UHS New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 2.02 Results of Operations and Financial Condition

On February 27, 2024, Universal Health Services, Inc. issued the press release attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Universal Health Services, Inc., press release, dated February 27, 2024.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit Index

Exhibit No. Exhibit
99.1 Universal Health Services, Inc., press release, dated February 27, 2024.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Universal Health Services, Inc.
By: /s/ Steve Filton
Name: Steve Filton
Title: Executive Vice President and<br><br>Chief Financial Officer

Date: February 27, 2024

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

February 27, 2024

CONTACT: Steve Filton
Chief Financial Officer
610-768-3300

UNIVERSAL HEALTH SERVICES, INC.

ANNOUNCES 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

AND 2024 OPERATING RESULTS FORECAST

Consolidated Results of Operations, As Reported and As Adjusted – Three-month periods ended December 31, 2023 and 2022:

KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $216.4 million, or $3.16 per diluted share, during the fourth quarter of 2023, as compared to $174.8 million, or $2.43 per diluted share, during the fourth quarter of 2022. Net revenues increased by 7.4% to $3.704 billion during the fourth quarter of 2023, as compared to $3.447 billion during the fourth quarter of 2022.

As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to UHS during the fourth quarter of 2023 was $214.9 million, or $3.13 per diluted share, as compared to $217.1 million, or $3.02 per diluted share, during the fourth quarter of 2022.

Included in our reported and adjusted net income attributable to UHS during the fourth quarter of 2023, were net incremental reimbursements (net of related provider taxes) of approximately $17.8 million, or $.20 per diluted share, recorded in connection with the recently approved Mississippi Hospital Access Program covering the period of July 1, 2023 through December 31, 2023. Included in our reported and adjusted net income attributable to UHS during the fourth quarter of 2022, was an aggregate favorable after-tax impact of approximately $19.6 million, or $.27 per diluted share, recorded in connection with $26.0 million of commercial insurance proceeds received during the quarter in connection with the following: (i) $15.7 million related to a business interruption and property damage claim at one of our behavioral health care facilities, and; (ii) $10.3 million related to a previously incurred information technology incident.

As reflected on the Supplemental Schedule, included in our reported results were unrealized after-tax gains of $1.5 million, or $.03 per diluted share ($1.9 million pre-tax), during the fourth quarter of 2023, and $1.8 million, or $.02 per diluted share ($2.3 million pre-tax) during the fourth quarter of 2022. These unrealized gains, which are included in “Other (income) expense, net”, resulted from increases in the market value of certain equity securities. In addition, as discussed below, included in our reported results during the fourth quarter of 2022 was an unfavorable after-tax impact of $44.1 million, or $.61 per diluted share, resulting from a provision for asset impairment ($57.6 million pre-tax which is included in other operating expenses) recorded to write-down the asset value of an acute care hospital, as discussed below.

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $476.9 million during the fourth quarter of 2023, as compared to $419.0 million during the fourth quarter of 2022. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, and provision for asset impairment (during the fourth quarter of 2022), was $473.4 million during the fourth quarter of 2023, as compared to $471.7 million during the fourth quarter of 2022.

Consolidated Results of Operations, As Reported and As Adjusted – Twelve-month periods ended December 31, 2023 and 2022:

Reported net income attributable to UHS was $717.8 million, or $10.23 per diluted share, during the full year 2023, as compared to $675.6 million, or $9.14 per diluted share, during 2022. Net revenues increased by 6.6% to $14.282 billion during the full year of 2023, as compared to $13.399 billion during 2022.

As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the twelve-month period ended December 31, 2023, was $739.4 million, or $10.54 per diluted share, as compared to $730.2 million, or $9.88 per diluted share, during the twelve-month period ended December 31, 2022.

As reflected on the Supplemental Schedule, included in our reported results were unrealized after-tax losses of $21.6 million, or $.31 per diluted share ($28.2 million pre-tax), during 2023, and $10.6 million, or $.14 per diluted share ($13.8 million pre-tax) during 2022. These unrealized losses, which are included in “Other (income) expense, net”, resulted from decreases in the market value of certain equity securities. In addition, included in our reported results during the full year of 2022 was an unfavorable after-tax impact of $44.1 million, or $.60 per diluted share, resulting from a provision for asset impairment, ($57.6 million pre-tax which is included in other operating expenses), as discussed below.

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”), was $1.714 billion during 2023, as compared to $1.594 billion during 2022. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, and provision for asset impairment (during 2022), was $1.742 billion during 2023, as compared to $1.662 billion during 2022.

Acute Care Services – Three and twelve-month periods ended December 31, 2023 and 2022:

During the fourth quarter of 2023, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased by 5.6% while adjusted patient days increased by 4.3%, as compared to the fourth quarter of 2022. At these facilities, during the fourth quarter of 2023, net revenue per adjusted admission increased by 3.7% while net revenue per adjusted patient day increased by 5.0%, as compared to the fourth quarter of 2022. Net revenues generated from our acute care services, on a same facility basis, increased by 9.7% during the fourth quarter of 2023, as compared to the fourth quarter of 2022.

During the twelve-month period ended December 31, 2023, at our acute care hospitals on a same facility basis, adjusted admissions increased by 7.6% while adjusted patient days increased by 4.7%, as compared to the year ended December 31, 2022. At these facilities, during the full year of 2023, net revenue per adjusted admission decreased by 0.6% while net revenue per adjusted patient day increased by 2.2%, as compared to 2022. Net revenues generated from our acute care services, on a same facility basis, increased by 7.6% during the full year of 2023, as compared to 2022.

Behavioral Health Care Services – Three and twelve-month periods ended December 31, 2023 and 2022:

During the fourth quarter of 2023, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 1.4% while adjusted patient days increased by 1.1%, as compared to the fourth quarter of 2022. At these facilities, during the fourth quarter of 2023, net revenue per adjusted admission increased by 5.8% and net revenue per adjusted patient day increased by 6.1%, as compared to the fourth quarter of 2022. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 7.2% during the fourth quarter of 2023, as compared to the fourth quarter of 2022.

During the twelve-month period ended December 31, 2023, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 3.2% while adjusted patient days increased by 2.1%, as compared to the comparable period of 2022. At these facilities, during the full year of 2023, net revenue per adjusted admission increased by 4.7% and net revenue per adjusted patient day increased by 5.9%, as compared to 2022. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 8.0% during 2023, as compared to 2022.

Net Cash Provided by Operating Activities and Liquidity:

Net Cash Provided by Operating Activities:

During the twelve-month period ended December 31, 2023, our net cash provided by operating activities was $1.268 billion as compared to $996 million during the full year of 2022. Included in the $272 million net

increase in our net cash provided by operating activities was a favorable change of $114 million in other working capital accounts due primarily to the timing of disbursements for accrued compensation and certain other accrued liabilities, as well as a favorable change of $76 million in accounts receivable.

Liquidity:

As of December 31, 2023, we had $701 million of aggregate available borrowing capacity pursuant to our $1.2 billion revolving credit facility, net of outstanding borrowings and letters of credit.

Stock Repurchase Program:

As of January 1, 2023, we had an aggregate remaining repurchase authorization of approximately $947 million pursuant to our stock repurchase program. Pursuant to the terms of our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.

During the fourth quarter of 2023, we have repurchased 1.13 million shares at an aggregate cost of approximately $157.3 million (approximately $139 per share) pursuant to the program. During the full year of 2023, we have repurchased approximately 3.86 million shares at an aggregate cost of approximately $524.5 million (approximately $136 per share) pursuant to the program.

As of December 31, 2023, we had an aggregate available repurchase authorization of approximately $423 million.

2024 Operating Results Forecast:

Reflected below is our 2024 forecasted range for consolidated net revenues, earnings before interest, taxes, depreciation & amortization, and the impacts of other income/expense and net income attributable to noncontrolling interests (“Adjusted EBITDA net of NCI”), net income attributable to UHS per diluted share (“EPS-diluted”) and capital expenditures.

Our 2024 forecasted range of net income attributable to UHS, and EPS-diluted, exclude certain items as described below because we do not believe we can forecast those items with sufficient accuracy. Adjusted EBITDA net of NCI, is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of our operating performance. Please see the Supplemental Non-GAAP Disclosures - 2024 Operating Results Forecast schedule as included herein for additional information and a reconciliation of our 2024 forecasted range of net income attributable to UHS to our 2024 forecasted range of Adjusted EBITDA net of NCI.

For the Year Ended

December 31, 2024

Low High
Net revenues $15.411 billion $15.706 billion
Adjusted EBITDA net of NCI $1.931 billion $2.019 billion
EPS-diluted $13.00 per share $14.00 per share
Capital expenditures $850 million $1.000 billion

Our 2024 operating results forecast contains a number of assumptions including, but not limited to, the following:

• The 2024 forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain equity securities, and other potential material items including, but not limited to, reserves for various matters including settlements, legal judgments and lawsuits, potential impacts of non-ordinary course acquisitions, divestitures, joint ventures or other strategic transactions, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets, other amounts that may be reflected in the current financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions. It is also subject to certain conditions

including those as set forth below in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.

• Our net revenues are estimated to be approximately $15.411 billion to $15.706 billion representing an increase of 7.9% to 10.0% over our 2023 net revenues of $14.282 billion.

• Our Adjusted EBITDA net of NCI is estimated to be approximately $1.931 billion to $2.019 billion representing an increase of 10.9% to 15.9% over our 2023 Adjusted EBITDA net of NCI of $1.742 billion.

• Our EPS-diluted range is estimated to be $13.00 per diluted share to $14.00 per diluted share, representing an increase of 23.3% to 32.8% over our adjusted net income attributable to UHS of $10.54 per diluted share for the year ended December 31, 2023, as calculated on the attached Supplemental Schedule.

• Our 2024 operating results forecast includes approximately $158 million of net reimbursements (net of related provider taxes) expected to be earned pursuant to the previously disclosed Nevada State Directed Payment program (“SDP”).

o The Medicaid managed care component of the Nevada SDP, our annual net reimbursements from which are expected to approximate $140 million during 2024, was approved by the Centers for Medicare and Medicaid Services (“CMS”) in late December, 2023, with an effective date of January 1, 2024. This component of the Nevada SDP requires annual approval by CMS and is subject to reconciliation by Nevada’s Division of Health Care Financing and Policy based on actual Medicaid managed care utilization during 2024. There can be no assurance that the Medicaid managed care component of the Nevada SDP will continue for any period after December 31, 2024, or that it will not be modified.

o The Medicaid fee for service upper payment limit component of the Nevada SDP, our annual net reimbursements from which are expected to approximate $18 million during 2024, was approved by CMS during the fourth quarter of 2023, with an effective date of July 1, 2023.

Provision for Asset Impairment (recorded during the fourth quarter of 2022):

Our financial statements for the three and twelve-month periods ended December 31, 2022, included a pre-tax provision for asset impairment of $57.6 million, which is included in other operating expenses on the accompanying consolidated statements of income. In March of 2023, we discontinued all inpatient operations at Desert Springs Hospital Medical Center, an acute care facility located in Las Vegas, Nevada. Since that time, we have continued providing emergency department services within a portion of the existing facility while we construct a new free-standing emergency department on the hospital's campus. The provision for asset impairment recorded during the fourth quarter of 2022 reduced the asset values of the facility's real estate and equipment to their estimated fair values.

Conference call information:

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on February 28, 2024. A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2023 were $14.282 billion. UHS ranked #311 on the Fortune 500; and #434 on Forbes’ list of America’s Largest Public Companies. UHS was again recognized as one of the World’s Most Admired Companies by Fortune.

Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones. Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has approximately 96,700 employees and, through its subsidiaries, operates 27 inpatient acute care hospitals, 333 inpatient behavioral health facilities, 48 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors, and Item 7-Forward-Looking Statements and Risk Factors, in our Form 10-K for the year ended December 31, 2023), may cause the results to differ materially from those anticipated in the forward-looking statements. These statements are subject to risks and uncertainties and therefore actual results may differ materially. Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:

• A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs. Payments from these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions. Changes to these programs, if adopted, could materially affect program payments which could materially impact our results of operations.

• The nationwide shortage of nurses and other clinical staff and support personnel experienced by healthcare providers in the past has been a significant operating issue facing us and other healthcare providers. In the past, the staffing shortage has, at times, required us to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. At certain facilities, particularly within our behavioral health care segment, there have been occasions when we were unable to fill all vacant positions and, consequently, we were required to limit patient volumes. The staffing shortage has required us to enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel or required us to hire expensive temporary personnel. Many of these factors, which had a material unfavorable impact on our results of operations during 2022, moderated to a certain degree during 2023.

• The increase in interest rates has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms. Additional increases in interest rates could have a significant unfavorable impact on our future results of operations and the resulting effect on the capital markets could adversely affect our ability to carry out our strategy.

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary

acquisitions, divestitures, joint ventures or other strategic transactions, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2023. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

(more)

Universal Health Services, Inc.
Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)
Three months Twelve months
ended December 31, ended December 31,
2023 2022 2023 2022
Net revenues $ 3,703,546 3,446,980 $ 14,281,976 13,399,370
Operating charges:
Salaries, wages and benefits 1,799,008 1,701,083 7,107,484 6,762,256
Other operating expenses 998,732 919,673 3,757,216 3,445,733
Supplies expense 393,878 381,936 1,532,828 1,474,339
Depreciation and amortization 145,481 148,353 568,041 581,861
Lease and rental expense 35,251 34,551 141,026 131,626
3,372,350 3,185,596 13,106,595 12,395,815
Income from operations 331,196 261,384 1,175,381 1,003,555
Interest expense, net 53,589 43,887 206,674 126,889
Other (income) expense, net (3,516 ) (4,838 ) 28,281 10,406
Income before income taxes 281,123 222,335 940,426 866,260
Provision for income taxes 61,501 51,966 221,119 209,278
Net income 219,622 170,369 719,307 656,982
Less: Net income (loss) attributable to noncontrolling interests ("NCI") 3,244 (4,451 ) 1,512 (18,627 )
Net income attributable to UHS $ 216,378 $ 174,820 $ 717,795 $ 675,609
Basic earnings per share attributable to UHS (a) $ 3.19 $ 2.45 $ 10.35 $ 9.23
Diluted earnings per share attributable to UHS (a) $ 3.16 $ 2.43 $ 10.23 $ 9.14
Universal Health Services, Inc.
--- --- --- --- --- --- --- --- --- --- --- --- ---
Footnotes to Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)
Three months Twelve months
ended December 31, ended December 31,
2023 2022 2023 2022
(a) Earnings per share calculation:
Basic and diluted:
Net income attributable to UHS $ 216,378 $ 174,820 $ 717,795 $ 675,609
Less: Net income attributable to unvested restricted share grants (66 ) (156 ) (308 ) (748 )
Net income attributable to UHS - basic and diluted $ 216,312 $ 174,664 $ 717,487 $ 674,861
Weighted average number of common shares - basic 67,809 71,165 69,321 73,118
Basic earnings per share attributable to UHS: $ 3.19 $ 2.45 $ 10.35 $ 9.23
Weighted average number of common shares 67,809 71,165 69,321 73,118
Add: Other share equivalents 741 627 804 714
Weighted average number of common shares and equiv. - diluted 68,550 71,792 70,125 73,832
Diluted earnings per share attributable to UHS: $ 3.16 $ 2.43 $ 10.23 $ 9.14
Universal Health Services, Inc.
--- --- --- --- --- --- --- --- --- --- --- --- ---
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Three Months ended December 31, 2023 and 2022
(in thousands, except per share amounts)
(unaudited)
Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")
Three months ended % Net Three months ended % Net
December 31, 2023 revenues December 31, 2022 revenues
Net income attributable to UHS $ 216,378 $ 174,820
Depreciation and amortization 145,481 148,353
Interest expense, net 53,589 43,887
Provision for income taxes 61,501 51,966
EBITDA net of NCI $ 476,949 12.9 % $ 419,026 12.2 %
Other (income) expense, net (3,516 ) (4,838 )
Provision for asset impairment - 57,550
Adjusted EBITDA net of NCI $ 473,433 12.8 % $ 471,738 13.7 %
Net revenues $ 3,703,546 $ 3,446,980
Calculation of Adjusted Net Income Attributable to UHS
Three months ended Three months ended
December 31, 2023 December 31, 2022
Per Per
Amount Diluted Share Amount Diluted Share
Net income attributable to UHS $ 216,378 $ 3.16 $ 174,820 $ 2.43
Plus/minus after-tax adjustments:
Unrealized gain on equity securities (1,470 ) (0.03 ) (1,778 ) (0.02 )
Provision for asset impairment - - 44,055 0.61
Subtotal adjustments (1,470 ) (0.03 ) 42,277 0.59
Adjusted net income attributable to UHS $ 214,908 $ 3.13 $ 217,097 $ 3.02
Universal Health Services, Inc.
--- --- --- --- --- --- --- --- --- --- ---
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Twelve Months ended December 31, 2023 and 2022
(in thousands, except per share amounts)
(unaudited)
Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")
Twelve months ended % Net Twelve months ended % Net
December 31, 2023 revenues December 31, 2022 revenues
Net income attributable to UHS $ 717,795 $ 675,609
Depreciation and amortization 568,041 581,861
Interest expense, net 206,674 126,889
Provision for income taxes 221,119 209,278
EBITDA net of NCI $ 1,713,629 12.0 % $ 1,593,637 11.9 %
Other (income) expense, net 28,281 10,406
Provision for asset impairment - 57,550
Adjusted EBITDA net of NCI $ 1,741,910 12.2 % $ 1,661,593 12.4 %
Net revenues $ 14,281,976 $ 13,399,370
Calculation of Adjusted Net Income Attributable to UHS
Twelve months ended Twelve months ended
December 31, 2023 December 31, 2022
Per Per
Amount Diluted Share Amount Diluted Share
Net income attributable to UHS $ 717,795 $ 10.23 $ 675,609 $ 9.14
Plus/minus after-tax adjustments:
Unrealized loss on equity securities $ 21,570 0.31 10,580 0.14
Provision for asset impairment - - 44,055 0.60
Subtotal adjustments 21,570 0.31 54,635 0.74
Adjusted net income attributable to UHS $ 739,365 $ 10.54 $ 730,244 $ 9.88
Universal Health Services, Inc.
--- --- --- --- --- --- ---
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
December 31, December 31,
2023 2022
Assets
Current assets:
Cash and cash equivalents $ 119,439 $ 102,818
Accounts receivable, net 2,238,265 2,017,722
Supplies 216,988 218,517
Other current assets 236,658 198,283
Total current assets 2,811,350 2,537,340
Property and equipment 11,777,047 11,085,852
Less: accumulated depreciation (5,652,518 ) (5,167,394 )
6,124,529 5,918,458
Other assets:
Goodwill 3,932,407 3,909,456
Deferred income taxes 85,626 68,397
Right of use assets-operating leases 433,962 454,650
Deferred charges 6,974 6,264
Other 572,754 599,623
Total Assets $ 13,967,602 $ 13,494,188
Liabilities and Stockholders' Equity
Current liabilities:
Current maturities of long-term debt $ 126,686 $ 81,447
Accounts payable and other liabilities 1,813,015 1,760,588
Operating lease liabilities 71,600 67,776
Federal and state taxes 2,046 4,608
Total current liabilities 2,013,347 1,914,419
Other noncurrent liabilities 584,007 487,669
Operating lease liabilities noncurrent 382,559 395,522
Long-term debt 4,785,783 4,726,533
Redeemable noncontrolling interest 5,191 4,695
UHS common stockholders' equity 6,149,001 5,920,582
Noncontrolling interest 47,714 44,768
Total equity 6,196,715 5,965,350
Total Liabilities and Stockholders' Equity $ 13,967,602 $ 13,494,188
Universal Health Services, Inc.
--- --- --- --- --- --- ---
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Twelve months
ended December 31,
2023 2022
Cash Flows from Operating Activities:
Net income $ 719,307 $ 656,982
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation & amortization 568,041 581,861
(Gain) loss on sale of assets and businesses (6,250 ) 584
Stock-based compensation expense 87,720 85,378
Provision for asset impairment 0 57,550
Changes in assets & liabilities, net of effects from acquisitions and dispositions:
Accounts receivable (182,444 ) (258,338 )
Accrued interest 1,193 1,835
Accrued and deferred income taxes (43,450 ) (29,510 )
Other working capital accounts (32,321 ) (146,692 )
Medicare accelerated payments and deferred CARES Act and other grants 2,978 2,391
Other assets and deferred charges 48,517 19,918
Other 39,133 (8,676 )
Accrued insurance expense, net of commercial premiums paid 183,462 174,723
Payments made in settlement of self-insurance claims (118,089 ) (141,983 )
Net cash provided by operating activities 1,267,797 996,023
Cash Flows from Investing Activities:
Property and equipment additions (743,055 ) (734,001 )
Proceeds received from sales of assets and businesses 24,187 12,001
Acquisition of businesses and property (3,728 ) (20,309 )
(Outflows) inflows from foreign exchange contracts that hedge our net U.K. investment (40,695 ) 94,913
Decrease in capital reserves of commercial insurance subsidiary 16 100
Net cash used in investing activities (763,275 ) (647,296 )
Cash Flows from Financing Activities:
Repayments of long-term debt (85,480 ) (89,367 )
Additional borrowings 185,100 705,321
Financing costs (308 ) (3,164 )
Repurchase of common shares (547,363 ) (832,918 )
Dividends paid (55,480 ) (58,449 )
Issuance of common stock 13,654 14,068
Profit distributions to noncontrolling interests (6,830 ) (5,391 )
(Purchase) sale of ownership interests by (from) minority members 2,762 (48,500 )
Net cash used in financing activities (493,945 ) (318,400 )
Effect of exchange rate changes on cash, cash equivalents and restricted cash 3,056 (8,424 )
Decrease in cash, cash equivalents and restricted cash 13,633 21,903
Cash, cash equivalents and restricted cash, beginning of period 200,837 178,934
Cash, cash equivalents and restricted cash, end of period $ 214,470 $ 200,837
Supplemental Disclosures of Cash Flow Information:
Interest paid $ 200,446 $ 120,136
Income taxes paid, net of refunds $ 257,896 $ 250,759
Noncash purchases of property and equipment $ 66,899 $ 72,064
Universal Health Services, Inc.
--- --- --- --- ---
Supplemental Statistical Information
(unaudited)
% Change % Change
Same Facility: 3 Months ended 12 Months ended
12/31/2023 12/31/2023
Acute Care Services
Revenues 9.7% 7.6%
Adjusted Admissions 5.6% 7.6%
Adjusted Patient Days 4.3% 4.7%
Revenue Per Adjusted Admission 3.7% -0.6%
Revenue Per Adjusted Patient Day 5.0% 2.2%
Behavioral Health Care Services
Revenues 7.2% 8.0%
Adjusted Admissions 1.4% 3.2%
Adjusted Patient Days 1.1% 2.1%
Revenue Per Adjusted Admission 5.8% 4.7%
Revenue Per Adjusted Patient Day 6.1% 5.9%
UHS Consolidated Fourth quarter ended Twelve months ended
12/31/2023 12/31/2022 12/31/2023 12/31/2022
Revenues $3,703,546 $3,446,980 $14,281,976 $13,399,370
EBITDA net of NCI $476,949 $419,026 $1,713,629 $1,593,637
EBITDA Margin net of NCI 12.9% 12.2% 12.0% 11.9%
Adjusted EBITDA net of NCI $473,433 $471,738 $1,741,910 $1,661,593
Adjusted EBITDA Margin net of NCI 12.8% 13.7% 12.2% 12.4%
Cash Flow From Operations $452,431 $297,304 $1,267,797 $996,023
Capital Expenditures $206,390 $164,446 $743,055 $734,001
Days Sales Outstanding 57 55
Debt $4,912,469 $4,807,980
UHS' Shareholders Equity $6,149,001 $5,920,582
Debt / Total Capitalization 44.4% 44.8%
Debt / EBITDA net of NCI (1) 2.87 3.02
Debt / Adjusted EBITDA net of NCI (1) 2.82 2.89
Debt / Cash From Operations (1) 3.87 4.83
(1) Latest 4 quarters.

Universal Health Services, Inc.

Acute Care Hospital Services

For the Three and Twelve Months ended

December 31, 2023 and 2022

(in thousands)

Same Facility Basis - Acute Care Hospital Services
Three months ended Three months ended Twelve months ended Twelve months ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues
Net revenues $ 2,032,535 100.0 % $ 1,852,000 100.0 % $ 7,840,740 100.0 % $ 7,284,868 100.0 %
Operating charges:
Salaries, wages and benefits 869,942 42.8 % 812,340 43.9 % 3,363,213 42.9 % 3,225,039 44.3 %
Other operating expenses 559,282 27.5 % 481,164 26.0 % 2,144,102 27.3 % 1,863,414 25.6 %
Supplies expense 338,790 16.7 % 321,747 17.4 % 1,303,018 16.6 % 1,226,294 16.8 %
Depreciation and amortization 93,287 4.6 % 94,919 5.1 % 358,308 4.6 % 369,493 5.1 %
Lease and rental expense 23,930 1.2 % 23,159 1.3 % 95,565 1.2 % 85,915 1.2 %
Subtotal-operating expenses 1,885,231 92.8 % 1,733,329 93.6 % 7,264,206 92.6 % 6,770,155 92.9 %
Income from operations 147,304 7.2 % 118,671 6.4 % 576,534 7.4 % 514,713 7.1 %
Interest expense, net (643 ) (0.0 )% (241 ) (0.0 )% (2,501 ) (0.0 )% 1,109 0.0 %
Other (income) expense, net 931 0.0 % 687 0.0 % 6,099 0.1 % 1,493 0.0 %
Income before income taxes $ 147,016 7.2 % $ 118,225 6.4 % $ 572,936 7.3 % $ 512,111 7.0 %
All Acute Care Hospital Services
Three months ended Three months ended Twelve months ended Twelve months ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues
Net revenues $ 2,087,503 100.0 % $ 1,939,239 100.0 % $ 8,081,402 100.0 % $ 7,646,749 100.0 %
Operating charges:
Salaries, wages and benefits 871,182 41.7 % 834,647 43.0 % 3,406,060 42.1 % 3,332,535 43.6 %
Other operating expenses 615,810 29.5 % 596,152 30.7 % 2,347,560 29.0 % 2,146,196 28.1 %
Supplies expense 338,732 16.2 % 329,129 17.0 % 1,317,917 16.3 % 1,264,688 16.5 %
Depreciation and amortization 93,479 4.5 % 97,557 5.0 % 367,644 4.5 % 383,115 5.0 %
Lease and rental expense 23,960 1.1 % 23,330 1.2 % 96,589 1.2 % 86,654 1.1 %
Subtotal-operating expenses 1,943,163 93.1 % 1,880,815 97.0 % 7,535,770 93.2 % 7,213,188 94.3 %
Income from operations 144,340 6.9 % 58,424 3.0 % 545,632 6.8 % 433,561 5.7 %
Interest expense, net (643 ) (0.0 )% (241 ) (0.0 )% (2,501 ) (0.0 )% 1,109 0.0 %
Other (income) expense, net 867 0.0 % 1,982 0.1 % 7,788 0.1 % 2,788 0.0 %
Income before income taxes $ 144,116 6.9 % $ 56,683 2.9 % $ 540,345 6.7 % $ 429,664 5.6 %

We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2023.

The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes; (ii) the impact of an asset impairment recorded in the three and twelve months ended December 31, 2022, and; (iv) certain other amounts including the results of facilities acquired or opened during the last twelve months.

Universal Health Services, Inc.

Behavioral Health Care Services

For the Three and Twelve Months ended

December 31, 2023 and 2022

(in thousands)

Same Facility - Behavioral Health Care Services
Three months ended Three months ended Twelve months ended Twelve months ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues
Net revenues $ 1,558,805 100.0 % $ 1,453,766 100.0 % $ 6,048,883 100.0 % $ 5,598,764 100.0 %
Operating charges:
Salaries, wages and benefits 852,069 54.7 % 794,776 54.7 % 3,343,222 55.3 % 3,088,108 55.2 %
Other operating expenses 296,915 19.0 % 262,606 18.1 % 1,163,365 19.2 % 1,078,918 19.3 %
Supplies expense 55,674 3.6 % 53,446 3.7 % 216,879 3.6 % 210,903 3.8 %
Depreciation and amortization 48,066 3.1 % 47,435 3.3 % 187,105 3.1 % 184,684 3.3 %
Lease and rental expense 11,143 0.7 % 10,689 0.7 % 43,785 0.7 % 41,951 0.7 %
Subtotal-operating expenses 1,263,867 81.1 % 1,168,952 80.4 % 4,954,356 81.9 % 4,604,564 82.2 %
Income from operations 294,938 18.9 % 284,814 19.6 % 1,094,527 18.1 % 994,200 17.8 %
Interest expense, net 1,108 0.1 % 1,212 0.1 % 4,434 0.1 % 5,169 0.1 %
Other (income) expense, net (1,132 ) (0.1 )% (4,921 ) (0.3 )% (3,426 ) (0.1 )% (6,343 ) (0.1 )%
Income before income taxes $ 294,962 18.9 % $ 288,523 19.8 % $ 1,093,519 18.1 % $ 995,374 17.8 %
All Behavioral Health Care Services
Three months ended Three months ended Twelve months ended Twelve months ended
December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022
Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues Amount % of Net<br>Revenues
Net revenues $ 1,615,543 100.0 % $ 1,494,543 100.0 % $ 6,190,921 100.0 % $ 5,729,758 100.0 %
Operating charges:
Salaries, wages and benefits 854,670 52.9 % 796,455 53.3 % 3,353,008 54.2 % 3,107,216 54.2 %
Other operating expenses 353,353 21.9 % 302,908 20.3 % 1,303,311 21.1 % 1,201,563 21.0 %
Supplies expense 55,713 3.4 % 53,471 3.6 % 217,310 3.5 % 211,786 3.7 %
Depreciation and amortization 49,180 3.0 % 47,752 3.2 % 189,297 3.1 % 186,555 3.3 %
Lease and rental expense 11,194 0.7 % 11,065 0.7 % 44,028 0.7 % 43,868 0.8 %
Subtotal-operating expenses 1,324,110 82.0 % 1,211,651 81.1 % 5,106,954 82.5 % 4,750,988 82.9 %
Income from operations 291,433 18.0 % 282,892 18.9 % 1,083,967 17.5 % 978,770 17.1 %
Interest expense, net 1,102 0.1 % 1,217 0.1 % 4,558 0.1 % 5,323 0.1 %
Other (income) expense, net (1,132 ) (0.1 )% (4,921 ) (0.3 )% (4,271 ) (0.1 )% (6,843 ) (0.1 )%
Income before income taxes $ 291,463 18.0 % $ 286,596 19.2 % $ 1,083,680 17.5 % $ 980,290 17.1 %

We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments, lawsuits and reserves established in connection with the government's investigation of our behavioral health care facilities, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and in the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2023.

The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months as well as the results of certain facilities that were closed or restructured during the past year.

Universal Health Services, Inc.
Selected Hospital Statistics
For the Three Months Ended
December 31, 2023 and 2022
AS REPORTED:
ACUTE BEHAVIORAL HEALTH
12/31/23 12/31/22 % change 12/31/23 12/31/22 % change
Hospitals owned and leased 27 28 -3.6 % 333 331 0.6 %
Average licensed beds 6,674 6,987 -4.5 % 24,194 24,228 -0.1 %
Average available beds 6,502 6,815 -4.6 % 24,094 24,128 -0.1 %
Patient days 403,117 401,363 0.4 % 1,600,740 1,560,526 2.6 %
Average daily census 4,381.7 4,362.6 0.4 % 17,399.3 16,962.2 2.6 %
Occupancy-licensed beds 65.7 % 62.4 % 5.1 % 71.9 % 70.0 % 2.7 %
Occupancy-available beds 67.4 % 64.0 % 5.3 % 72.2 % 70.3 % 2.7 %
Admissions 82,918 81,314 2.0 % 118,487 112,272 5.5 %
Length of stay 4.9 4.9 -1.5 % 13.5 13.9 -2.8 %
Inpatient revenue $ 11,408,639 $ 10,182,914 12.0 % $ 2,647,158 $ 2,536,091 4.4 %
Outpatient revenue 7,566,625 6,452,816 17.3 % 275,128 257,601 6.8 %
Total patient revenue 18,975,264 16,635,730 14.1 % 2,922,286 2,793,692 4.6 %
Other revenue 234,117 203,952 14.8 % 83,153 82,734 0.5 %
Gross revenue 19,209,381 16,839,682 14.1 % 3,005,439 2,876,426 4.5 %
Total deductions 17,121,878 14,900,443 14.9 % 1,389,896 1,381,883 0.6 %
Net revenue $ 2,087,503 $ 1,939,239 7.6 % $ 1,615,543 $ 1,494,543 8.1 %
SAME FACILITY:
ACUTE BEHAVIORAL HEALTH
12/31/23 12/31/22 % change 12/31/23 12/31/22 % change
Hospitals owned and leased 27 27 0.0 % 331 331 0.0 %
Average licensed beds 6,674 6,705 -0.5 % 24,031 24,102 -0.3 %
Average available beds 6,502 6,533 -0.5 % 23,931 24,002 -0.3 %
Patient days 403,117 387,228 4.1 % 1,563,374 1,549,906 0.9 %
Average daily census 4,381.7 4,209.0 4.1 % 16,993.2 16,846.8 0.9 %
Occupancy-licensed beds 65.7 % 62.8 % 4.6 % 70.7 % 69.9 % 1.2 %
Occupancy-available beds 67.4 % 64.4 % 4.6 % 71.0 % 70.2 % 1.2 %
Admissions 82,918 78,639 5.4 % 112,712 111,427 1.2 %
Length of stay 4.9 4.9 -1.3 % 13.9 13.9 -0.3 %
Universal Health Services, Inc.
--- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Selected Hospital Statistics
For the Twelve Months Ended
December 31, 2023 and 2022
AS REPORTED:
ACUTE BEHAVIORAL HEALTH
12/31/23 12/31/22 % change 12/31/23 12/31/22 % change
Hospitals owned and leased 27 28 -3.6 % 333 331 0.6 %
Average licensed beds 6,691 6,923 -3.4 % 24,224 24,259 -0.1 %
Average available beds 6,519 6,751 -3.4 % 24,124 24,159 -0.1 %
Patient days 1,576,074 1,569,611 0.4 % 6,336,927 6,230,124 1.7 %
Average daily census 4,318.0 4,300.3 0.4 % 17,361.4 17,068.8 1.7 %
Occupancy-licensed beds 64.5 % 62.1 % 3.9 % 71.7 % 70.4 % 1.9 %
Occupancy-available beds 66.2 % 63.7 % 4.0 % 72.0 % 70.7 % 1.9 %
Admissions 322,218 311,537 3.4 % 472,307 459,245 2.8 %
Length of stay 4.9 5.0 -2.9 % 13.4 13.6 -1.1 %
Inpatient revenue $ 44,687,035 $ 40,004,670 11.7 % $ 10,648,996 $ 10,116,566 5.3 %
Outpatient revenue 29,858,874 24,813,718 20.3 % 1,087,595 1,031,370 5.5 %
Total patient revenue 74,545,909 64,818,388 15.0 % 11,736,591 11,147,936 5.3 %
Other revenue 948,994 806,587 17.7 % 303,546 292,018 3.9 %
Gross revenue 75,494,903 65,624,975 15.0 % 12,040,137 11,439,954 5.2 %
Total deductions 67,413,501 57,978,226 16.3 % 5,849,216 5,710,196 2.4 %
Net revenue $ 8,081,402 $ 7,646,749 5.7 % $ 6,190,921 $ 5,729,758 8.0 %
SAME FACILITY:
ACUTE BEHAVIORAL HEALTH
12/31/23 12/31/22 % change 12/31/23 12/31/22 % change
Hospitals owned and leased 27 27 0.0 % 331 331 0.0 %
Average licensed beds 6,604 6,640 -0.5 % 24,016 24,014 0.0 %
Average available beds 6,432 6,468 -0.6 % 23,916 23,914 0.0 %
Patient days 1,564,390 1,512,013 3.5 % 6,289,388 6,175,143 1.9 %
Average daily census 4,286.0 4,142.5 3.5 % 17,231.2 16,918.2 1.9 %
Occupancy-licensed beds 64.9 % 62.4 % 4.0 % 71.7 % 70.5 % 1.8 %
Occupancy-available beds 66.6 % 64.0 % 4.0 % 72.0 % 70.7 % 1.8 %
Admissions 319,829 300,507 6.4 % 468,131 454,441 3.0 %
Length of stay 4.9 5.0 -2.8 % 13.4 13.6 -1.1 %
Universal Health Services, Inc.
--- --- --- --- --- --- --- --- --- --- --- --- ---
Supplemental Non-GAAP Disclosures
2024 Operating Results Forecast
(in thousands, except per share amounts)
Forecast For The Year Ending December 31, 2024
% Net % Net
Low revenues High revenues
Net revenues $ 15,411,000 $ 15,706,000
Net income attributable to UHS (a) $ 865,709 $ 932,123
Depreciation and amortization 605,204 605,204
Interest expense 196,338 196,338
Other (income) expense, net (11,133 ) (11,133 )
Provision for income taxes 274,883 295,971
Adjusted EBITDA net of NCI (b) $ 1,931,001 12.5 % $ 2,018,503 12.9 %
Net income attributable to UHS, per diluted share (a) $ 13.00 $ 14.00
Shares used in computing diluted earnings per share 66,594 66,594
(a) Forecasted net income attributable to UHS/per diluted share exclude the following items because we do not believe we can forecast these items with sufficient accuracy. Such items include: the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain equity securities, and other potential material items including, but not limited to, reserves for various matters including settlements, legal judgments and lawsuits, potential impacts of non-ordinary course acquisitions, divestitures, joint ventures or other strategic transactions, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets, other amounts that may be reflected in the current financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions. Forecasted net income attributable to UHS/per diluted share is also subject to certain conditions including those as set forth in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.
(b) Adjusted EBITDA net of NCI is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of operating performance.